文献速递眼底病与葡萄膜炎

持续抑制VEGF-A治疗糖尿病黄斑水肿的消退时间进程

Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab.
PubMed 文献 · Am J Ophthalmol · 2026-10-27

基于Pagoda临床试验的回顾性分析,评估Port Delivery Platform with ranibizumab(PDS)持续释放雷珠单抗对糖尿病黄斑水肿(DME)的疗效。调整意向治疗人群中,PDS组87.9%和IVT-PDS组85.3%患眼末次访视时CST恢复正常(≤325 µm),平均正常化时间分别为21.3周和20.6周。56例PDS详细OCT分析显示93%患眼CST正常化(中位17周),84%患眼中央1mm内视网膜内液消除(中位68周),仅3眼末次访视时DME控制不佳。

要点

  • 持续抑制VEGF-A对绝大多数DME患者有效,但水肿消退可能缓慢。
  • PDS组和IVT-PDS组CST正常化比例分别为87.9%和85.3%。
  • 部分患者水肿消退缓慢,不应误判为对抗VEGF-A治疗无反应。

核心结论

  • 持续抑制VEGF-A足以有效治疗绝大多数DME患者,但部分患者水肿消退缓慢,可能造成对抗VEGF-A治疗反应不佳的假象。
  • 在DME中,应将「对抗VEGF-A治疗无反应」改为「缓慢反应」。

研究设计与样本

  • 回顾性分析前瞻性临床试验Pagoda(NCT04108156)数据。
  • 调整意向治疗人群:PDS组n=272,IVT-PDS组n=238;详细OCT分析纳入56例PDS患者(来自8个中心)。

主要发现

  • PDS组平均随访107.7周,IVT-PDS组100.7周。
  • 末次访视时CST恢复正常(≤325 µm)的比例:PDS组87.9%,IVT-PDS组85.3%;平均正常化时间分别为21.3周和20.6周。
  • 56例PDS患者中,93%患眼CST正常化(中位17周),84%患眼中央1mm内视网膜内液消除(中位68周)。
  • 仅3/56眼末次访视时DME控制不佳;两组所有患眼CST随时间均下降,但部分出现波动,少数先改善后恶化。

关键数值与推荐

  • CST正常范围定义为≤325 µm。
  • CST正常化比例:PDS组87.9%,IVT-PDS组85.3%。
  • CST正常化平均时间:PDS组21.3周,IVT-PDS组20.6周。
  • 56例PDS患者中CST正常化中位时间17周,视网膜内液消除中位时间68周。

临床怎么用

  • 对DME患者持续抑制VEGF-A治疗时,应认识到水肿消退可能缓慢,避免过早判定为无反应。
  • 部分患者CST波动或先改善后恶化,需长期随访观察。

局限性

  • 回顾性分析,详细OCT分析仅纳入56例PDS患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the incidence of poor responsiveness to VEGF-A suppression in eyes with diabetic macular edema (DME) by evaluating the effect of continuous delivery of ranibizumab via the Port Delivery Platform with ranibizumab (PDS) in individual patients enrolled in the Pagoda clinical trial. DESIGN: Retrospective analysis of prospective clinical trial data SUBJECTS: DME patients enrolled in Pagoda (NCT04108156). METHODS: Change in central subfield thickness (CST) and best-corrected visual acuity (BCVA) over time was evaluated for the adjusted intent-to-treat (aITT) population in the Pagoda trial. Optical coherence tomography (OCT) images obtained at each visit were analyzed for 56 PDS subjects from 8 sites to determine the time course of changes in intraretinal and subretinal fluid. MAIN OUTCOME MEASURES: CST, BCVA, and time to resolution of edema. RESULTS: In the aITT population the mean duration of follow up was 107.7 weeks in the PDS arm (n=272) and 100.7 weeks the IVT-PDS arm (n=238). The percentage of eyes with CST improvement into the normal range (≤325 µm) by the last visit was 87.9% in the PDS group and 85.3% in the IVT-PDS arm with mean time to normalization of 21.3 weeks and 20.6 weeks, respectively. All eyes in both arms showed reduction in CST over time although some exhibited periods of CST fluctuation and a few in each arm showed initial improvement followed by worsening at last follow up. In the eyes of 56 PDS patients that had detailed analysis of OCTs, normalization of CST occurred in 93% at a median of 17 weeks and elimination of intraretinal fluid in the central 1mm occurred in 84% at a median of 68 weeks. Only 3 of 56 eyes had poorly controlled DME at last follow up. CONCLUSIONS: Sustained suppression of VEGF-A is sufficient to effectively treat DME in the vast majority of patients, but edema resolution may be slow in some patients giving the false impression of poor response to anti-VEGF-A treatment. In DME, the term unresponsive to anti-VEGF-A treatment should be replaced by slowly responsive.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Rustam Z, Khanani AM, Mojumder O, et al. Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab. Am J Ophthalmol. 2026. PMID: 42946032. doi:10.1016/j.ajo.2026.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。